Last updated on July 2017

ACTICOAT for the Treatment of Burns and Chronic Wounds


Brief description of study

The aim of the study is to evaluate participant reported quality of life, safety, and overall performance with ACTICOAT in a clinical setting. ACTICOAT is a silver coated antimicrobial barrier wound dressing for the treatment of a variety of wound types. It is widely used in routine clinical practice within the UK. ACTICOAT is CE marked and will be used within the intended indications for use. The proposed study is required for regulatory purposes. Primary Objective: To evaluate change in health related quality of life, associated with treatment. The primary outcome measure / endpoint will be change in EQ-5D 5L mean single index utility scores from baseline to 3 weeks. The study will also seek to gather and report relevant safety and performance data and evaluate change, where applicable, for outcomes including: clinical signs and symptoms of infection; wound length / width / depth; wound healing measures; tissue staining; pain, adherence, and pain on application / removal; wear time; adverse events and device deficiencies. In total 25 participants will be recruited into the trial, comprising a minimum of 8 participants with a full or partial thickness burn and a minimum of 8 participants with a full or partial thickness chronic wound. All participants will have their wound dressed using ACTICOAT, and will be followed-up for 3 weeks.

Clinical Study Identifier: NCT02852148

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Judith Horner, PhD

Leeds Wounds Research Unit
Leeds, United Kingdom
  Connect »

Judith Horner, PhD

Northumbria Healthcare NHS Foundation Trust
Northumberland, United Kingdom
  Connect »

Judith Horner, PhD

The Mid Yorkshire Hospitals NHS Trust
Wakefield, United Kingdom
  Connect »